Literature DB >> 14715636

Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level.

Florence Magrangeas1, Marie-Laure Cormier, Géraldine Descamps, Nadège Gouy, Laurence Lodé, Marie-Paule Mellerin, Jean-Luc Harousseau, Régis Bataille, Stéphane Minvielle, Hervé Avet-Loiseau.   

Abstract

Although most multiple myeloma (MM) cases are characterized by the detection of a monoclonal immunoglobulin in the serum, about 15% of the patients present only immunoglobulin light chains, detected either in the urine or serum or both. These patients are designated as having light-chain (LC) MM. Using fiber-fluorescent in situ hybridization, and in contrast to patients and myeloma cell lines secreting heavy chains (who presented a legitimate functional IgH rearrangement in every case), LC MM never displayed a functional IgH recombination. Interestingly, most LC MM cases presented one IgH allele with a germline configuration (including the DJ region), the second allele being usually involved in an illegitimate recombination. Of note, most of these translocations occurred close to (or at) switch regions, even though in some cases, breakpoints involving nonswitch regions were observed. Thus, this study clearly showed that LC MM is due to the absence of legitimate IgH rearrangement at the DNA level, reflecting possible abnormalities in the IgH gene recombinations during B-cell maturation. Furthermore, it showed that this defect did not prevent the activation of the switch process because most of 14q32 translocations observed in LC MM occurred at switch regions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715636     DOI: 10.1182/blood-2003-07-2501

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

1.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

2.  Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Authors:  S Kumar; L Zhang; A Dispenzieri; S Van Wier; J A Katzmann; M Snyder; E Blood; R DeGoey; K Henderson; R A Kyle; A R Bradwell; P R Greipp; S V Rajkumar; R Fonseca
Journal:  Leukemia       Date:  2010-06-03       Impact factor: 11.528

Review 3.  Non-secretory multiple myeloma: from biology to clinical management.

Authors:  Megan Murray Dupuis; Sascha A Tuchman
Journal:  Onco Targets Ther       Date:  2016-12-15       Impact factor: 4.147

4.  Clonal Expansion and Interrelatedness of Distinct B-Lineage Compartments in Multiple Myeloma Bone Marrow.

Authors:  Leo Hansmann; Arnold Han; Livius Penter; Michaela Liedtke; Mark M Davis
Journal:  Cancer Immunol Res       Date:  2017-08-02       Impact factor: 11.151

Review 5.  Non-Secretory Myeloma: Ready for a new Definition?

Authors:  Alessandro Corso; Silvia Mangiacavalli
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-08-18       Impact factor: 2.576

Review 6.  An Overview of Light Chain Multiple Myeloma: Clinical Characteristics and Rarities, Management Strategies, and Disease Monitoring.

Authors:  Abdul Rafae; Mustafa N Malik; Muhammad Abu Zar; Seren Durer; Ceren Durer
Journal:  Cureus       Date:  2018-08-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.